Charles J. Casamento, a director at Eton Pharmaceuticals, Inc. (NASDAQ:ETON), sold common stock valued at approximately $5.35 million on November 10, 2026, following the exercise of options to acquire shares. The sale comes at a time when ETON is trading at $67.54, close to its 52-week high of $68.38, after delivering a 299% return over the past year. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, placing it among companies on the most overvalued list.
Mr. Casamento disposed of 80,555 shares of Eton Pharmaceuticals common stock. The sales were executed at prices ranging from $64.3287 to $67.8695 per share, resulting in a total transaction value of $5,345,071.
Before these sales, Mr. Casamento acquired 80,555 shares of common stock through the exercise of stock options. These options were exercised at prices ranging from $3.58 to $8.61 per share, for a total acquisition value of $438,076. The options had various vesting schedules, becoming fully exercisable between February 20, 2020, and February 7, 2023.
Following these transactions, Mr. Casamento holds no direct beneficial ownership in Eton Pharmaceuticals common stock.
In other recent news, Eton Pharmaceuticals reported a significant third-quarter performance, surpassing both earnings and revenue forecasts. The company announced adjusted earnings of $0.50 per share on revenue of $57.9 million, outperforming analyst estimates of $0.31 per share and $41.97 million in revenue. This marks a substantial beat, with revenue exceeding forecasts by 37.96% and earnings per share surpassing expectations by 61.29%. Additionally, Eton Pharmaceuticals revised its full-year revenue guidance upward, anticipating more than $175 million, up from the previous guidance of more than $145 million. The company also projected that its adjusted EBITDA margin should exceed 40%. These developments highlight the company’s robust financial performance and strategic outlook.